Announced
Completed
Financials
Tags
Friendly
United States
Private Equity
cancer treatment
Single Bidder
biotech
Biotechnology
Domestic
Minority
Completed
Private
Acquisition
early stage therapies
Synopsis
Private equity firms Cobro Ventures and Perceptive Advisors led a $150m Series B funding round in C4 Therapeutics, a biotechnology company. Additional new equity investors in the round included Adage Capital Management, Axil Capital, Bain Capital Life Sciences, Commodore Capital, 3E Bioventures Capital, HBM Healthcare Investments, Lightchain Capital, Logos Capital, Mizuho Securities Principal Investment, Nextech, RA Capital Management, RTW Investments, Sphera Funds Management, Taiwania Capital Management, Yonjin Venture, and funds and accounts managed by T. Rowe Price Associates, and Janus Henderson Investors. Existing investors also participated. “C4 Therapeutics is a pioneer in this exciting and promising new protein degradation space. With their strong science and world class team we have no doubt that they will be able to bring powerful new therapeutics to patients and we are excited to collaborate with C4T on this important mission," Adam Stone, Perceptive Advisors Chief Investment Officer.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.